

AMENDMENTS TO THE CLAIMS:


This listing of claims below as previously presented will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

1-11. (Canceled)

12. (Previously Presented) A tricyclic derivative represented by the following <Formula 1> or pharmaceutically acceptable salts thereof:

<Formula 1>







wherein

(1) R_1 is $-T_1-B_1$;

wherein

T_1 is $-N(R_5)C(X_2)-$, wherein X_2 is O; and R_5 is H or C_1 - C_5 alkyl group; and

B_1 is selected from the group consisting of




and

wherein,


R_6 is halogen, hydroxy, C_1 - C_3 alkoxy, amino, nitro, cyano or C_1 - C_3 lower alkyl group;

R_8 is H, halogen, hydroxy, C_1 - C_3 alkoxy, amino, nitro, cyano or C_1 - C_3 lower alkyl group;

R_7 is halogen, hydroxyl, mercapto, -ONO, ONO_2 or SNO;




is selected from the group consisting of



C1

,



C7

,



C11

,

and



C12


;

wherein, C1 (pyridyl group) is substituted at position 2 and 6 or position 2 and 5, C7 (pyrrolyl group) is substituted at position 2 and 5 or position 2 and 4, C11 (thiophenyl group) and C12 (furanlyl group) are substituted symmetrically or asymmetrically;

Z_1 is C_1 - C_{10} straight-chain or branched-chain alkyl group;

T_2 is $-X_1-C(X_2)-$, in that X_1 and X_2 are each independently O;

B_2 is selected from the group consisting of:



n_2 is an integer of 0-3; and

n_3 is an integer of 1-5;

(2) R_2 and R_3 are each independently H, $-PO_3H_2$, phosphonate, sulfate, C_3 - C_7 cycloalkyl, C_2 - C_7 alkenyl, C_2 - C_7 alkynyl, C_1 - C_7 alkanoyl, C_1 - C_7 straight-chain or branched-chain alkyl or sugar, in which sugar is a monosaccharide such as glucuronyl, glucosyl or galactosyl;

(3) R_4 is OCH_3 , SCH_3 or $NR_{10}R_{11}$, in which R_{10} and R_{11} are each independently H or C_{1-5} alkyl; and

(4) X is O or S.

13. (Previously Presented) The tricyclic derivative or pharmaceutically acceptable salts thereof as set forth in claim 12,

wherein

R₂ and R₃ are each independently C₃-C₇ cycloalkyl or C₁-C₇ alkyl; and
R₄ is SCH₃ or OCH₃.

14-15. (Canceled)

16. (Previously Presented) The tricyclic derivative or pharmaceutically acceptable salts thereof as set forth in claim 12, wherein Z₁ is C₂-C₅ straight-chain or branched-chain alkyl group or cycloalkyl group having substituent.

17. (Previously Presented) A tricyclic derivative or pharmaceutically acceptable salts thereof, wherein the tricyclic derivative comprises:

1)

6-nitrooxymethyl-N-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-nicotineamide;

2) 5-nitrooxymethyl-furan-2-carboxylic

acid-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-amide;

5) 6-nitrooxymethyl-pyridine-2-carboxylic

acid-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-amide;

6) 5-nitrooxymethyl-thiophene-2-carboxylic

acid-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-amide;

8)

N-[(7S)-3-ethoxy-1,2-dimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-2-fluoro-3-nitrooxymethyl-benzamide;

9)

2-fluoro-N-[(7S)-3-isopropoxy-1,2-dimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benz o[a]heptalen-7-yl]-3-nitrooxymethyl-benzamide;

10)

2-fluoro-3-nitrooxymethyl-N-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-benzamide;

11)

N-[(7S)-3-cyclopentyloxy-1,2-dimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-2-fluoro-3-nitrooxymethyl-benzamide;

12)

3-fluoro-5-nitrooxymethyl-N-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-benzamide;

13)

N-[(7S)-3-ethoxy-1,2-dimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-3-fluoro-5-nitrooxymethyl-benzamide;

14)

3-fluoro-N-[(7S)-3-isopropoxy-1,2-dimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-5-nitrooxymethyl-benzamide;

15)

N-[(7S)-3-cyclopentyloxy-1,2-dimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-3-fluoro-5-nitrooxymethyl-benzamide;

16)

4-fluoro-3-nitrooxymethyl-N-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-benzamide;

17)

2-fluoro-5-nitrooxymethyl-N-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-benzamide;

18)

3-hydroxy-5-nitrooxymethyl-N-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-benzamide;

20)

2-hydroxy-4-nitrooxymethyl-N-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-benzamide;

21) 4-nitrooxymethyl-thiophene-2-carboxylic acid

[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-amide;

22) 3-nitrooxymethyl-thiophene-2-carboxylic acid

[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-amide;

25) 3-nitrooxybenzoic

acid-5-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl-carbamoyl]-pyridine-2-yl-methylester;

26) 4-nitrooxybutyric

acid-5-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl-carbamoyl]-pyridine-2-yl-methylester;

27) 3-nitrooxymethyl-benzoic

acid-6-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl-carbamoyl]-pyridine-2-yl-methylester;

28) 4-nitrooxybutyric

acid-6-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl-carbamoyl]-pyridine-2-yl-methylester;

29) 3-nitrooxymethyl-benzoic

acid-2-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl-carbamoyl]-phenylester;

30) 4-nitrooxybutyric

acid-2-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl-carbamoyl]-phenylester;

31) 3-nitrooxymethyl-benzoic

acid-3-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl-carbamoyl]-phenylester;

32) 4-nitrooxybutyric

acid-3-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl-carbamoyl]-phenylester;

33) 3-nitrooxymethyl-benzoic

acid-3-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl
-carbamoyl]-benzylester;

34) 4-nitrooxybutyric

acid-3-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl
-carbamoyl]-benzylester;

37)

3-fluoro-5-nitrosooxymethyl-N-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahy
dro-benzo[a]heptalen-7-yl]-benzamide;

39)

3-fluoro-5-nitrosothiomethyl-N-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahy
dro-benzo[a]heptalen-7-yl]-benzamide;

40)

3-fluoro-5-nitrooxymethyl-N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydro-benzo[a]hept
alen-7-yl]-benzamide;

42)

3-fluoro-N-methyl-5-nitrooxymethyl-N-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9
-tetrahydro-benzo[a]heptalen-7-yl]-benzamide;

43)

2-(3-fluoro-5-nitrooxymethyl-phenyl)-N-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,
9-tetrahydro-benzo[a]heptalen-7-yl]-acetamide; or

44)

2-(2-fluoro-5-nitrooxymethyl-phenyl)-N-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,
9-tetrahydro-benzo[a]heptalen-7-yl]-acetamide.

18. (Previously Presented) An anticancer agent composition or anti-proliferation agent composition comprising the tricyclic derivatives-or pharmaceutically acceptable salts thereof as set forth in claim 12 as an effective ingredient and a pharmaceutically acceptable excipient.

19. (Previously Presented) An angiogenesis inhibitor composition comprising the tricyclic derivatives or pharmaceutically acceptable salts thereof as set forth in claim 12 as an effective

ingredient and a pharmaceutically acceptable excipient.

20. (Previously Presented) An anticancer agent composition or anti-proliferation agent composition comprising the tricyclic derivatives-or pharmaceutically acceptable salts thereof as set forth in claim 17 as an effective ingredient and a pharmaceutically acceptable excipient.

21. (Previously Presented) An angiogenesis inhibitor composition comprising the tricyclic derivatives or pharmaceutically acceptable salts thereof as set forth in claim 17 as an effective ingredient and a pharmaceutically acceptable excipient.